Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$24.82 +0.9%	$22.38	$13.40 ▼ $25.23	$4.19B	0.7	2.18 million shs	1.80 million shs
ACLX Arcellx	$69.10 -2.0%	$67.52	$47.86 ▼ $107.37	$3.81B	0.28	660,839 shs	481,150 shs
AKRO Akero Therapeutics	$48.28 -4.3%	$52.34	$21.34 ▼ $58.40	$3.85B	-0.28	1.43 million shs	1.19 million shs
AMPH Amphastar Pharmaceuticals	$27.36 +14.9%	$23.35	$20.39 ▼ $53.96	$1.27B	0.76	572,211 shs	1.82 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.55%	+17.25%	+40.41%	+57.39%
ACLX Arcellx	0.00%	-0.90%	+2.20%	+18.49%	+19.39%
AKRO Akero Therapeutics	0.00%	+4.32%	-2.15%	+21.50%	+103.96%
AMPH Amphastar Pharmaceuticals	0.00%	+12.26%	+9.93%	-2.18%	-44.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9896 of 5 stars	3.3	3.0	0.0	2.6	4.2	2.5
ACLX Arcellx	2.4017 of 5 stars	3.6	2.0	0.0	2.7	2.5	0.0
AKRO Akero Therapeutics	4.0174 of 5 stars	3.5	3.0	4.7	3.3	0.8	0.0
AMPH Amphastar Pharmaceuticals	3.8197 of 5 stars	2.1	2.0	3.7	2.4	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	16.34% Upside
ACLX Arcellx	3.13	Buy	$114.31	65.42% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.95% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$30.00	9.65% Upside

Current Analyst Ratings Breakdown

Latest AMPH, ACAD, ACLX, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	ACLX Arcellx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/31/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$93.00 ➝ $133.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.37	$0.71 per share	34.90	$4.40 per share	5.64
ACLX Arcellx	$76.81M	49.58	N/A	N/A	$8.41 per share	8.22
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
AMPH Amphastar Pharmaceuticals	$731.97M	1.74	$5.75 per share	4.76	$15.23 per share	1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	18.66	32.66	6.72	21.80%	14.69%	9.41%	N/A
ACLX Arcellx	-$107.35M	-$3.42	N/A	N/A	N/A	-329.93%	-43.04%	-27.41%	8/14/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-16.62%	-15.27%	N/A
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	10.25	8.32	N/A	18.64%	20.76%	9.68%	N/A

Latest AMPH, ACAD, ACLX, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	ACLX Arcellx	-$1.03	-$0.94	+$0.09	-$0.94	$16.76 million	$7.55 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
ACLX Arcellx	N/A	3.81	3.81
AKRO Akero Therapeutics	0.03	16.80	16.80
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
AKRO Akero Therapeutics	N/A
AMPH Amphastar Pharmaceuticals	65.09%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ACLX Arcellx	8.35%
AKRO Akero Therapeutics	7.07%
AMPH Amphastar Pharmaceuticals	27.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	120.97 million	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.90 million	Optionable

AMPH, ACAD, ACLX, and AKRO Headlines

Recent News About These Companies

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

August 11 at 6:00 AM | accessnewswire.comA

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 12.1% - Here's Why

August 10 at 2:00 PM | marketbeat.com

Piper Sandler Issues Pessimistic Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

August 10 at 2:21 AM | americanbankingnews.com

Amphastar Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations

August 9 at 12:54 PM | finance.yahoo.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript

August 9 at 12:54 PM | msn.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler

August 9 at 8:56 AM | marketbeat.com

Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ...

August 9 at 2:35 AM | finance.yahoo.com

Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures

August 8 at 11:33 AM | msn.com

Amphastar (AMPH) Q2 2025 Earnings Call Transcript

August 8 at 11:33 AM | fool.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%

August 8 at 11:33 AM | finance.yahoo.com

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

August 8 at 10:40 AM | zacks.com

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

August 8 at 2:00 AM | seekingalpha.com

Amphastar Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 8 at 2:41 AM | seekingalpha.com

Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say

August 7, 2025 | zacks.com

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

August 7, 2025 | zacks.com

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

August 7, 2025 | accessnewswire.comA

18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd

August 7, 2025 | marketbeat.com

Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 6, 2025 | finance.yahoo.com

Amphastar Pharmaceuticals (AMPH) Projected to Post Earnings on Thursday

August 6, 2025 | americanbankingnews.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

August 5, 2025 | marketbeat.com

Investors in Amphastar Pharmaceuticals (NASDAQ:AMPH) have unfortunately lost 47% over the last year

August 5, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, ACAD, ACLX, and AKRO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$24.82 +0.22 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$24.78 -0.04 (-0.16%)

As of 06:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$69.10 -1.40 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$69.99 +0.89 (+1.29%)

As of 04:34 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Akero Therapeutics NASDAQ:AKRO

$48.28 -2.18 (-4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$47.84 -0.44 (-0.91%)

As of 06:54 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Amphastar Pharmaceuticals NASDAQ:AMPH

$27.36 +3.55 (+14.91%)

Closing price 04:00 PM Eastern

Extended Trading

$27.38 +0.02 (+0.07%)

As of 06:04 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time